Three Seasons Wealth LLC Purchases New Stake in Novo Nordisk A/S (NYSE:NVO)

Three Seasons Wealth LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, Holdings Channel.com reports. The fund purchased 3,783 shares of the company’s stock, valued at approximately $325,000.

Several other hedge funds also recently added to or reduced their stakes in NVO. M. Kulyk & Associates LLC boosted its holdings in Novo Nordisk A/S by 3.9% in the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company’s stock valued at $274,000 after purchasing an additional 119 shares in the last quarter. Center for Financial Planning Inc. boosted its position in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Tradewinds Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 2.6% during the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company’s stock worth $429,000 after purchasing an additional 124 shares during the period. Exencial Wealth Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 0.5% in the 4th quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company’s stock valued at $1,987,000 after purchasing an additional 124 shares in the last quarter. Finally, Indie Asset Partners LLC lifted its stake in shares of Novo Nordisk A/S by 4.2% in the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company’s stock valued at $269,000 after purchasing an additional 126 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $62.59 on Friday. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market cap of $280.87 billion, a price-to-earnings ratio of 19.02, a PEG ratio of 0.90 and a beta of 0.61. The business’s 50 day moving average is $74.03 and its two-hundred day moving average is $90.18.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were paid a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. The ex-dividend date was Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 49.54%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on NVO. Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.